CNS Drugs

, Volume 32, Issue 8, pp 797–806 | Cite as

Amantadine Extended-Release (GOCOVRI): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease

  • Julia PaikEmail author
  • Susan J. Keam
Adis Drug Evaluation


Amantadine extended-release (ER) capsules (GOCOVRI) are approved in the USA for the treatment of dyskinesia in patients with Parkinson’s disease (PD) receiving levodopa-based therapy, with or without concomitant dopaminergic medications. With a recommended dosage of 274 mg once daily at bedtime, this new formulation of amantadine allows a more gradual time to peak plasma amantadine concentration and higher drug concentrations in the morning and throughout the day, the time period when levodopa-induced dyskinesia (LID) is the most problematic. In 13-week (EASE LID 3) and 25-week (EASE LID), randomized, double-blind phase III trials, once-daily amantadine ER 274 mg capsules significantly improved levodopa-induced dyskinesia (LID), while also increasing ON time without troublesome dyskinesia and reducing OFF time and ON time with troublesome dyskinesia from the morning and throughout the day, compared with placebo. In the ongoing, longer-term EASE LID 2 study (with interim results reported for up to 64 weeks), patients previously treated with amantadine ER maintained improvements in LID, as per patient-reported Unified Dyskinesia Rating Scale (UDysRS) scoring and ON/OFF times. Amantadine ER was generally well tolerated, with most adverse events (AEs) being transient and mild or moderate in severity. The most common (incidence > 15%) treatment-related AEs in the placebo-controlled trials were hallucinations, dizziness, dry mouth and peripheral oedema. While long-term data are needed to establish durability of response and safety, including the completion of the ≈ 2-year EASE LID 2 study, current evidence indicates that amantadine ER is an effective treatment option to consider in the management of LID in PD patients.



During the peer review process, the manufacturer of amantadine ER (GOCOVRI) was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

Julia Paik and Susan J. Keam are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.


  1. 1.
    Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol. 2012;25(4):433–47.CrossRefGoogle Scholar
  2. 2.
    Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.CrossRefGoogle Scholar
  3. 3.
    Schaeffer E, Pilotto A, Berg D. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson’s disease. CNS Drugs. 2014;28(12):1155–84.CrossRefGoogle Scholar
  4. 4.
    Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs. 2016;76(7):759–77.CrossRefGoogle Scholar
  5. 5.
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.CrossRefGoogle Scholar
  6. 6.
    Perez-Lloret S, Negre-Pages L, Damier P, et al. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol. 2017;24(12):1532–8.CrossRefGoogle Scholar
  7. 7.
    Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol. 2011;69(6):919–27.CrossRefGoogle Scholar
  8. 8.
    Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665–77.CrossRefGoogle Scholar
  9. 9.
    Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25(10):1357–63.CrossRefGoogle Scholar
  10. 10.
    Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50(5):1323–6.CrossRefGoogle Scholar
  11. 11.
    Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82(4):300–7.CrossRefGoogle Scholar
  12. 12.
    Vertical Pharmaceuticals LLC. OSMOLEX ER (amantadine) extended-release tablets, for oral use—US prescribing information. 2018. Accessed 19 Jul 2018.
  13. 13.
    Adamas Pharma LLC. GOCOVRI (amantadine) extended release capsules, for oral use—US prescribing information. 2017. Accessed 19 Jul 2018.
  14. 14.
    Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–9.CrossRefGoogle Scholar
  15. 15.
    Parkes JD, Zilkha KJ, Marsden P, et al. Amantadine dosage in treatment of Parkinson’s disease. Lancet. 1970;1(7657):1130–3.CrossRefGoogle Scholar
  16. 16.
    Hauser RA, Pahwa R, Wargin W, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once-daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2018. Scholar
  17. 17.
    Adamas Pharma LLC. Adamas announces FDA approval of GOCOVRI™ as first and only medication for the treatment of dyskinesia in Parkinson's disease patients [media release]. 24 Aug 2017.
  18. 18.
    Endo Pharmaceuticals Inc. SYMMETREL (amantadine hydrochloride): US prescribing information. 2009. Accessed 19 Jul 2018.
  19. 19.
    Duty S. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson’s disease. CNS Drugs. 2012;26(12):1017–32.CrossRefGoogle Scholar
  20. 20.
    Calabresi P, Di Filippo M, Ghiglieri V, et al. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord. 2008;23(Suppl 3):S570–9.CrossRefGoogle Scholar
  21. 21.
    Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26(3):503–13.CrossRefGoogle Scholar
  22. 22.
    Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93(9):457–62.CrossRefGoogle Scholar
  23. 23.
    Brigham EF, Johnston TH, Brown C, et al. Pharmacokinetic/pharmacodynamic analysis of amantadine for levodopa-induced dyskinesia: correlation of therapeutic plasma concentrations from multiple species with humans [abstract no. S45.006]. Neurology. 2018;90(15 Suppl.):S45.006.Google Scholar
  24. 24.
    Parsons CG, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology. 1995;34(10):1239–58.CrossRefGoogle Scholar
  25. 25.
    Stoof JC, Booij J, Drukarch B, et al. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol. 1992;213(3):439–43.CrossRefGoogle Scholar
  26. 26.
    Matsubayashi H, Swanson KL, Albuquerque EX. Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther. 1997;281(2):834–44.PubMedGoogle Scholar
  27. 27.
    Adamas Pharmaceuticals Inc. GOCOVRI: (amantadine) extended release capsules. 2018. Accessed 19 Jul 2018.
  28. 28.
    Pahwa R, Tanner CM, Hauser RA, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30(6):788–95.CrossRefGoogle Scholar
  29. 29.
    Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017;32(12):1701–9.CrossRefGoogle Scholar
  30. 30.
    Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941–9.CrossRefGoogle Scholar
  31. 31.
    Hauser RA, Pahwa R, Tanner CM, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 2 study): interim results of an open-label safety study. J Parkinsons Dis. 2017;7(3):511–22.CrossRefGoogle Scholar
  32. 32.
    Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRefGoogle Scholar
  33. 33.
    Elmer LW, Juncos JL, Singer C, et al. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson’s disease. CNS Drugs. 2018;32(4):387–98.CrossRefGoogle Scholar
  34. 34.
    Pahwa R, Hauser RA, Tanner CM, et al. ADS-5102 reduces ON time with troublesome dyskinesia and OFF time throughout the waking day: time course analysis [poster no. 61]. In: 2nd Pan American Parkinson’s Disease and Movement Disorders Congress. 2018.Google Scholar
  35. 35.
    Isaacson S, Fahn S, Pahwa R, et al. Parkinson’s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102. Mov Disord Clin Pract. 2018;5(2):183–90.CrossRefGoogle Scholar
  36. 36.
    Nazem S, Siderowf AD, Duda JE, et al. Suicidal and death ideation in Parkinson’s disease. Mov Disord. 2008;23(11):1573–9.CrossRefGoogle Scholar
  37. 37.
    Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. 2018. Accessed 19 Jul 2018.
  38. 38.
    Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother. 1983;23(3):458–64.CrossRefGoogle Scholar
  39. 39.
    Claassen DO, Kutscher SJ. Sleep disturbances in Parkinson’s disease patients and management options. Nat Sci Sleep. 2011;3:125–33.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations